TRC-150094 is a synthetic compound that displays the capacity to stimulate energy expenditure. TRC-150094 increases whole body energy expenditure, increases mitochondrial fatty acid oxidation (FAO), and reduces abdominal adiposity in rats fed a high-fat diet. TRC-150094 attenuates the progression of hypertension, insulin resistance, dysglycemia, and atherogenic dyslipidemia, factors reported to signify significant cardiovascular (CV) risk amongst viscerally obese dysglycemic subjects. Moreover, at organ level, TRC150094 reduced steatohepatitis, reduced progression of nephropathy, and preserved cardiac contractile function. Pharmacological profile of TRC-150094 may constitute a promising new class of molecules that may have a potential beneficial therapeutic approach for the treatment of nontraditional CV risk factors and may reduce residual risk in viscerally obese dysglycemic patients. Moreover, the observed metabolic and functional effects on skeletal muscle suggest that TRC-150094 as a therapy may help to facilitate adherence to prescribed exercise, which would remain the mainstay along with diet control in such patients. Simultaneous systemic administration of TRC-150094 to rats receiving an high-fat diet results in a reduction in fat accumulation within the liver and a marked reduction in adipose tissue mass. TRC-150094 is in phase-III clinical trials for the treatment of diabetes mellitus, hypertension and dyslipidaemias (adjunctive treatment) in India.